Gt Biopharma, INC 8-K filings

GT Biopharma has amended its bylaws to lower the shareholder quorum requirement from a majority to one-third of outstanding shares.

GT Biopharma has received a 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement.

GT Biopharma has entered into a $3.8 million clinical trial agreement with the University of Minnesota to advance its GTB-5550 TriKE candidate for solid tumors.

GT Biopharma, Inc. announced a restatement of its Q2 and Q3 2025 financial statements due to an accounting error related to Greenshoe Rights.

GT Biopharma, Inc. received a notice from Nasdaq regarding non-compliance with the $1 minimum bid price requirement, initiating a 180-day compliance period.

GT Biopharma announced its third quarter 2025 financial results, highlighting progress in its GTB-3650 clinical trial and anticipated IND submission for GTB-5550.

GT Biopharma, Inc. announced that all holders of its Series L 10% Convertible Preferred Stock have waived their redemption rights, completing a series of agreements.

GT Biopharma, Inc. announced that certain holders of its Series L 10% Convertible Preferred Stock have waived their redemption rights, removing a potential financial obligation for the company.

GT Biopharma, Inc. announced the renewal of Michael Breen's employment agreement as Executive Chairman and Chief Executive Officer for a two-year term, effective April 29, 2025.

GT Biopharma, Inc. announced that its stockholders approved all five proposals, including the election of directors and key equity issuances, at its annual meeting held on July 24, 2025.

GT Biopharma, Inc. has amended its common shares purchase agreement to increase an investor's beneficial ownership limit to 9.99% and appointed David C. Mun-Gavin as an independent director, chairing the Compensation Committee.

GT Biopharma, Inc. has amended its previously announced private placement, increasing the aggregate purchase price to $5.95 million and adding a new purchaser, while also expanding the potential for future funding through Greenshoe Rights.

GT Biopharma reports significant changes to its board of directors, including new appointments, resignations, and committee assignments.

GT Biopharma enters into a securities purchase agreement for a private placement of preferred stock and warrants totaling $5.45 million.

GT Biopharma has appointed Michael Breen, who has been serving as Interim CEO since March 2022, as its permanent Chief Executive Officer, effective April 29, 2025.

GT Biopharma issued a pre-funded warrant to Cytovance Biologics for services, allowing Cytovance to purchase up to 326,251 shares of common stock.

GT Biopharma incentivizes warrant holders to exercise existing warrants by offering new Series A and B warrants, aiming to raise approximately $0.7 million for working capital.

GT Biopharma has announced the first patient has been dosed in a Phase 1 trial for GTB-3650, a second-generation TriKE therapy targeting hematologic malignancies.

GT Biopharma received a notice from Nasdaq stating that its stockholders' equity has fallen below the required minimum of $2.5 million, potentially leading to delisting.

GT Biopharma has partnered with the University of Minnesota to conduct a Phase 1 clinical trial for its GTB-3650 TriKE therapy targeting high-risk blood cancers, with the university sponsoring the Investigational New Drug application.

GT Biopharma has announced that Dr. Jeffrey Miller has transitioned from Consulting Chief Medical Officer and Consulting Chief Scientific Officer to Consulting Senior Medical Director, effective September 16, 2024, due to a conflict of interest policy at the University of Minnesota.

GT Biopharma announced FDA clearance for its Investigational New Drug application for GTB-3650, allowing the company to proceed with a Phase 1 clinical trial.

GT Biopharma held its annual meeting on June 25, 2024, where shareholders voted on the election of directors, ratification of auditors, and executive compensation.

GT Biopharma has appointed Alan L. Urban as its new Chief Financial Officer, effective June 3, 2024, following the termination of Manu Ohri's employment.

GT Biopharma has entered into a definitive agreement for a $3.2 million registered direct offering of common stock and warrants.

GT Biopharma amended its agreement with Cytovance Biologics, increasing the ownership limit of GT Biopharma's common stock from 4.9% to 9.9%.

GT Biopharma has announced a 1-for-30 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.